Neuroprotection of midbrain dopaminergic cells in MPTP-treated mice after near-infrared light treatment

Journal of Comparative Neurology

Volumn 518, Issue 1, 2010, Pages 25-40

  Shaw, Victoria E ^a   Spana, Sharon ^a   Ashkan, Keyoumars ^c   Benabid, Alim Louis ^b   Stone, Jonathan ^a   Baker, Gary E ^d   Mitrofanis, John ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b CEA LETI   (France)

^c KING S COLLEGE HOSPITAL   (United Kingdom)

^d CITY UNIVERSITY   (United Kingdom)

Author keywords

Basal ganglia; Cell death; Hypothalamus; Parkinson's disease; Substantia nigra; Zona incerta

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; SODIUM CHLORIDE; TYROSINE 3 MONOOXYGENASE; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; NEUROPROTECTIVE AGENT; NEUROTOXIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BAGG ALBINO MOUSE; BRAIN TISSUE; CELL SPECIFICITY; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; ELECTROMAGNETIC RADIATION; HYPOTHALAMUS; IMMUNOCHEMISTRY; MALE; MESENCEPHALON; MOUSE; NEAR INFRARED RADIATION; NERVE DEGENERATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RADIATION EXPOSURE; SUBSTANTIA NIGRA; ZONA INCERTA; ANIMAL; CYTOLOGY; DRUG EFFECT; HUMAN; INFRARED RADIATION; INTOXICATION; METABOLISM; NERVE CELL; PARKINSON DISEASE; PATHOLOGY; PATHOPHYSIOLOGY; PHOTOTHERAPY; SUBTHALAMIC NUCLEUS;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; DOPAMINE; DOPAMINE AGENTS; HUMANS; INFRARED RAYS; MALE; MESENCEPHALON; MICE; MICE, INBRED BALB C; MPTP POISONING; NEURONS; NEUROPROTECTIVE AGENTS; NEUROTOXINS; PARKINSON DISEASE; PHOTOTHERAPY; SUBSTANTIA NIGRA; SUBTHALAMUS; TYROSINE 3-MONOOXYGENASE;

EID: 74049123851     PISSN: 00219967     EISSN: 10969861     Source Type: Journal    
DOI: 10.1002/cne.22207     Document Type: Article

References (65)

1. Aguirre JA, Andbjer B, Gonzalez-Baron S, Hansson A, Stromberg I, Agnati LF, Fuxe K. 2001. Group I mGluR antagonist AIDA protects nigral DA cells from MPTP-induced injury. Neuroreport 12:2615-2617.
2. Airaksinen MS, Thoenen H, Meyer M. Vulnerability of midbrain dopaminergic neurons in calbindin-D28k-deficient mice: lack of evidence for a neuroprotective role of endogenous calbindin in MPTP-treated and weaver mice. 1997. Eur J Neurosci 9:120 -127.
3. Ashkan K, Wallace B, Bell BA, Benabid AL. 2004. Deep brain stimulation of the subthalamic nucleus in Parkinson's disease 1993-2003: where are we 10 years on? Br J Neurosurg 18: 19-34.
4. Ashkan K, Wallace BA, Mitrofanis J, Pollo C, Brard PY, Fagret D, Benabid AL. 2007. SPECT imaging, immunohistochemical and behavioural correlations in the primate models of Parkinson's disease. Parkin Rel Disord 13:266-275.
5. Assia E, Rosner M, Belkin M, Solomon A, Schwartz M. 1989. Temporal parameters of low energy laser irradiation for optimal delay of post-traumatic degeneration of rat optic nerve. Brain Res 476:205-212.
6. Barreiro-Iglesias A, Villar-Cerviño V, Anadón R, Rodicio MC. 2008. Descending brain-spinal cord projections in a primitive vertebrate, the lamprey: cerebrospinal fluid-contacting and dopaminergic neurons. J Comp Neurol 511:711-723.
7. Beauvoit B, Kitai T, Chance B. 1994. Contribution of the mitochondrial compartment to the optical properties of the rat liver: a theoretical and practical approach. Biophys J 67: 2501-2510.
8. Bergman H, Deuschl G. 2002. Pathophysiology of Parkinson's disease: from clinical neurology to basic neuroscience and back. Mov Disord 17:S28-40.
9. Bezard E, Dovero S, Imbert C, Boraud T, Gross CE. 2000. Spontaneous long-term compensatory dopaminergic sprouting in MPTP-treated mice. Synapse 38:363-368.
10. Björklund A, Lindvall O. 1984. Dopamine-containing systems in the CNS. In: Björklund A, Hökfelt T, eds. Handbook of chemical neuroanatomy: classical transmitter in rat, Vol. 2. Amsterdam: Elsevier/North Holland. p 55-122.
11. Bjorklund A, Rosenblad C, Winkler C, Kirik D. 1997. Studies on neuroprotective and regenerative effects of GDNF in a partial lesion model of Parkinson's disease. Neurobiol Dis 4:186-200.
12. Blandini F, Nappi G, Tassorelli C, Martignoni E. 2000. Functional changes of the basal ganglia circuitry in Parkinson's disease. Prog Neurobiol 62:63-88.
13. Bloem BR, Irwin I, Buruma OJ, Haan J, Roos RA, Tetrud JW, Langston JW. 1990. The MPTP model: versatile contributions to the treatment of idiopathic Parkinson's disease. J Neurol Sci 97: 273-293.
14. Breit S, Bouali-Benazzouz R, Benabid AL, Benazzouz A. 2001. Unilateral lesion of the nigrostriatal pathway induces an increase of neuronal activity of the pedunculopontine nucleus, which is reversed by the lesion of the subthalamic nucleus in the rat. Eur J Neurosci 14:1833-1842.
15. Desmet KD, Paz DA, Corry JJ, Eells JT, Wong-Riley MT, Henry MM, Buchmann EV, Connelly MP, Dovi JV, Liang HL, Henshel DS, Yeager RL, Millsap DS, Lim J, Gould LJ, Das R, Jett M, Hodgson BD, Margolis D, Whelan HT. 2006. Clinical and experimental applications of NIR-LED photobiomodulation. Photomed Laser Surg 24:121-128.
16. Eells JT, Henry MM, Summerfelt P, Wong-Riley MT, Buchmann EV, Kane M, Whelan NT, Whelan HT. 2003. Therapeutic photobiomodulation for methanol-induced retinal toxicity. Proc Natl Acad Sci U S A 100:3439-3444.
17. Eells J, DeSmet K, Kirk D. 2007. Photobiomodulation for the treatment of retinal injury and retinal degenerative diseases. In: Waynant R, Tata D, eds. Light-Assisted Tissue Regeneration and Therapy II Conference Proceedings. Berlin: Springer.
18. Fitzpatrick E, Ashkan K, Wallace BA, Benabid AL, Mitrofanis J. 2005. Differential survival patterns among midbrain dopaminergic cells of MPTP-treated monkeys and 6OHDA-lesioned rats. Anat Embryol (Berl) 210:101-123.
19. German DC, Manaye KF, Sonsall PK, Brooks BA. 1992. Midbrain, dopaminergic cell loss in Parkinson's disease and MPTPinduced parkinsonism: sparing of calbindin-D28k-containing cells. Ann N Y Acad Sci 648:42-62.
20. Gibb WR, Lees AJ, Jenner P, Marsden CD. 1986. The dopamine neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) produces histological lesions in the hypothalamus of the common marmoset. Neurosci Lett 65:79-83.
21. Giménez E, Lavado A, Giraldo P, Montoliu L. 2003. Tyrosinase gene expression is not detected in mouse brain outside the retinal pigment epithelium cells. Eur J Neurosci 18:2673-2676.
22. Gonzalez A, Smeets WJ. 1991. Comparative analysis of dopamine and tyrosine hydroxylase immunoreactivities in the brain of two amphibians, the anuran Rana ridibunda and the urodele Pleurodeles waltlii. J Comp Neurol 303:457-477.
23. Haber SN, Ryoo H, Cox C, Lu W. 1995. Subsets of midbrain dopaminergic neurons in monkeys are distinguished by different levels of mRNA for the dopamine transporter: comparison with the mRNA for the D2 receptor, tyrosine hydroxylase and calbindin immunoreactivity. J Comp Neurol 362:400-410.
24. Hamblin MR, Demidova TN. 2006. Mechanisms of low level light therapy. In: Hamblin MR, Waynart RW, Anders J, eds. Mechanisms for low-light therapy. Proc SPIE 6140.
25. Hirsch EC, Faucheux B, Damier P, Mouatt-Prigent A, Agid Y. 1997. Neuronal vulnerability in Parkinson's disease. J Neural Transm Suppl 50:79-88.
26. Jackson-Lewis V, Jakowec M, Burke RE, Przedborski S. 1995. Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1236-tetrahydropyridine. Neurodegeneration 4:257-269.
27. Jacobowitz DM, Palkovits M. 1974. Topographic atlas of catecholamine and acetylcholinesterase containing neurons in the rat brain. I. Forebrain (telencephalon, diencephalon). II. Hindbrain (mesencephalon, rhombencephalon). J Comp Neurol 157:13-28; 29-42.
28. Jankovic J. 2005. Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations. Mov Disord 20:S11-16.
29. Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, Kosel S, Przuntek H, Epplen JT, Schols L, Riess O. 1998. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 18:106-118.
30. Lampl Y, Zivin JA, Fisher M, Lew R, Welin L, Dahlof B, Borenstein P, Andersson B, Perez J, Caparo C, Ilic S, Oron U. 2007. Infrared laser therapy for ischemic stroke: a new treatment strategy: results of the NeuroThera. Effectiveness and Safety Trial-1 (NEST-1). Stroke 38:1843-1849.
31. Langston JW. 1996. The etiology of Parkinson's disease with emphasis on the MPTP story. Neurology 47:S153-160.
32. LeWitt PA. 2006. Neuroprotection for Parkinson's disease. J Neural Transm Suppl 71:113-122.
33. Liang HL, Whelan HT, Eells JT, Meng H, Buchmann E, Lerch-Gaggl A, Wong-Riley M. 2006. Photobiomodulation partially rescues visual cortical neurons from cyanide-induced apoptosis. Neuroscience 139:639-649.
34. Liang HL, Whelan HT, Eells JT, Wong-Riley MT. 2008. Nearinfrared light via light-emitting diode treatment is therapeutic against rotenone- and 1-methyl-4-phenylpyridinium ioninduced neurotoxicity. Neuroscience 153:963-974.
35. Luquin N, Mitrofanis J. 2008. Does the cerebral cortex exacerbate dopaminergic cell death in the substantia nigra of 6OHDA-lesioned rats? Parkin Related Disord 14:213-223.
36. Ma J, Shaw VE, Mitrofanis J. 2009. Does melatonin help save dopaminergic cells in MPTP-treated mice? Parkin Relat Disord 15:307-314.
37. Matzuk MM, Saper CB. 1985. Preservation of hypothalamic dopaminergic neurons in Parkinson's disease. Ann Neurol 18: 552-555.
38. McRitchie DA, Cartwright HR, Halliday GM. 1997. Specific A10 dopaminergic nuclei in the midbrain degenerate in Parkinson's disease. Exp Neurol 144:202-213.
39. Melamed E, Rosenthal J, Globus M, Cohen O, Frucht Y, Uzzan A. 1985. Mesolimbic dopaminergic neurons are not spared by MPTP neurotoxicity in mice. Eur J Pharmacol 114:97-100.
40. Mitchell IJ, Clarke CE, Boyce S, Robertson RG, Peggs D, Sambrook MA, Crossman AR. 1989. Neural mechanisms underlying parkinsonian symptoms based upon regional uptake of 2-deoxyglucose in monkeys exposed to 1-methyl-4-phenyl-1,2, 3,6-tetrahydropyridine. Neuroscience 32:213-226.
41. Mitrofanis J, Vigny A, Stone J. 1988. Distribution of catecholaminergic cells in the retina of the rat, guinea pig, cat, and rabbit: independence from ganglion cell distribution. J Comp Neurol 267:1-14.
42. Mogi M, Harada M, Kojima K, Kiuchi K, Nagatsu T. 1988. Effects of systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine to mice on tyrosine hydroxylase, L-3,4-dihydroxyphenylalanine decarboxylase, dopamine betahydroxylase, and monoamine oxidase activities in the striatum and hypothalamus. J Neurochem 50:1053-1056.
43. Orieux G, Francois C, Feger J, Yelnik J, Vila M, Ruberg M, Agid Y, Hirsch EC. 2000. Metabolic activity of excitatory parafascicular and pedunculopontine inputs to the subthalamic nucleus in a rat model of Parkinson's disease. Neuroscience 97:79-88.
44. Oron U, Yaakobi T, Oron A, Mordechovitz D, Shofti R, Hayam G, Dror U, Gepstein L, Wolf T, Haudenschild C, Haim SB. 2001. Low-energy laser irradiation reduces formation of scar tissue after myocardial infarction in rats and dogs. Circulation 103: 296-301.
45. Oron A, Oron U, Chen J, Eilam A, Zhang C, Sadeh M, Lampl Y, Streeter J, DeTaboada L, Chopp M. 2006. Low-level laser therapy applied transcranially to rats after induction of stroke significantly reduces long-term neurological deficits. Stroke 37:2620-2624.
46. Passarella S, Casamassima E, Molinari S, Pastore D, Quagliariello E, Catalano IM, Cingolani A. 1984. Increase of proton electrochemical potential and ATP synthesis in rat liver mitochondria irradiated in vitro by helium-neon laser. FEBS Lett 175:95-99.
47. Paul G, Meissner W, Rein S, Harnack D, Winter C, Hosmann K, Morgenstern R, Kupsch A. 2004. Removal of the subthalamic nucleus protects dopaminergic phenotype but not cell survival in a rat model of Parkinson's disease. Exp Neurol 185: 272-280.
48. Paxinos G, Franklin KBJ. 2001. The mouse brain in sterotaxic coordinates, 2nd ed. San Diego: Academic Press.
49. Piallat B, Benazzouz A, Benabid AL. 1996. Subthalamic nucleus lesion in rats prevents dopaminergic nigral neuron degeneration after striatal 6-OHDA injection: behavioural and immunohistochemical studies. Eur J Neurosci 8:1408-1414.
50. Przedborski S, Jackson-Lewis V, Djaldetti R, Liberatore G, Vila M, Vukosavic S, Almer G. 2000. The parkinsonian toxin MPTP: action and mechanism. Restor Neurol Neurosci 16:135-142.
51. Riederer P, G Gille, Müller T, Przuntek H, Reichmann H, Riess O, Schwartz A, Schwarz G, Vogt T. 2002. Practical importance of neuroprotection in Parkinson's disease. J Neurol 249:53-56.
52. Rinne JO. 1993. Nigral degeneration in Parkinson's disease. Mov Disord 8(Suppl 1):S31-35.
53. Sánchez-González MA, García-Cabezas MA, Rico B, Cavada C. 2005. The primate thalamus is a key target for brain dopamine. J Neurosci 25:6076-6083.
54. Schapira AH. 2009. Molecular and clinical pathways to neuroprotection of dopaminergic drugs in Parkinson disease. Neurology 17:S44-50.
55. Schmidt N, Ferger B. 2001. Neurochemical findings in the MPTP model of Parkinson disease. J Neural Trans 108:1263-1282.
56. Steiner H, Kitai ST. 2001. Unilateral striatal dopamine depletion: time-dependent effects on cortical function and behavioural correlates. Eur J Neurosci 14:1390-1391.
57. Takada M, Matsumura M, Kojima J, Yamaji Y, Inase M, Tokuno H, Nambu A, Imai H. 2000. Protection against dopaminergic nigrostriatal cell death by excitatory input removal. Eur J Neurosci 12:1771-1780.
58. Thomas B, Mohanakumar KP. 2004. Melatonin protects against oxidative stress caused by 1-methyl-4-phenyl-1236-tetrahydropyridine in the mouse nigrostriatum. J Pineal Res 36:25-32.
59. Wallace BA, Ashkan K, Heise CE, Foote KD, Torres N, Mitrofanis J, Benabid AL. 2007. Survival of midbrain dopaminergic cells after lesion or deep brain stimulation of the subthalamic nucleus in MPTP-treated monkeys. Brain 130:2129-2145.
60. Whelan HT, Smits RL Jr, Buchman EV, Whelan NT, Turner SG, Margolis DA, Cevenini V, Stinson H, Ignatius R, Martin T, Cwiklinski J, Philippi AF, Graf WR, Hodgson B, Gould L, Kane M, Chen G, Caviness J. 2001. Effect of NASA light-emitting diode irradiation on wound healing. J Clin Laser Med Surg 19:305-314.
61. Wilden L, Karthein R. 1998. Import of radiation phenomena of electrons and therapeutic low-level laser in regard to the mitochondrial energy transfer. J Clin Laser Med Surg 16:159-165.
62. Wong-Riley MT, Bai X, Buchmann E, Whelan HT. 2001. Light-emitting diode treatment reverses the effect of TTX on cytochrome oxidase in neurons. Neuroreport 12:3033-3037.
63. Wong-Riley MT, Liang HL, Eells JT, Chance B, Henry MM, Buchmann E, Kane M, Whelan HT. 2005. Photobiomodulation directly benefits primary neurons functionally inactivated by toxins: role of cytochrome c oxidase. J Biol Chem 280:4761-4771.
64. Ying R, Liang HL, Whelan HT, Eells JT, Wong-Riley MT. 2008. Pretreatment with near-infrared light via light-emitting diode provides added benefit against rotenone- and MPP+-induced neurotoxicity. Brain Res 1243:167-173.
65. Zuddas A, Corsini GU, Schinelli S, Johannessen JN, di Porzio S, Kopin IJ. 1989. MPTP treatment combined with ethanol or acetaldehyde selectively destroys dopaminergic neurons in mouse substantia nigra. Brain Res 501:1-10.